Drug intelligence / Profile preview

tissue-plasminogen activator

Development stage: Approved
Lead developer: Genentech
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Tissue-plasminogen activator (tPA) is a protein that facilitates the breakdown of blood clots by converting plasminogen into plasmin, the major enzyme responsible for clot dissolution. It is used in the treatment of ischemic strokes, pulmonary embolism, and myocardial infarction. tPA is a serine protease found on endothelial cells lining blood vessels and can be manufactured using recombinant biotechnology techniques.

Brand names: Activase
Other names: tPA

Targets

Fibrin (Factor Ia)PLG (Plasminogen)

Beyond the preview

Go deeper on tissue-plasminogen activator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tissue-plasminogen activator.

Explore the full profile